Friday, June 19, 2026
THMA Pharmacy Growth pharmaceutical event banner
← Back to Events
Tier 1 Global Networking: High CARDIOLOGY CONCLUDED

THMA Pharmacy Growth — 2026 — Carlsbad, USA

Carlsbad, CA . The Health Management Academy's (THMA) Pharmacy Growth Collaborative brings health system pharmacy leaders and select industry executives .

Carlsbad, USA June 3 – June 5, 2026
400+ Attendees
6 Presentations
4 Companies
4 Drugs
All Events

Presentation data updated Jun 10, 2026, 5:33 AM UTC

Nova Event Impact Score
47 /100
  • Media coverage 10/20
  • Speaker quality 15/20
  • Pipeline relevance 1/20
  • Historical influence 13/20
  • Company participation 8/20

Key Takeaways

Key Themes

cardiologyTHMAPipeline announcementsPartnership deals

Key Companies

AstraZenecaArcturus TherapeuticsBristol Myers SquibbImmatics

Key Drugs

tixagevimabazacitidinedanuglipronsemaglutide

Key Markets

US Americas

Key Opportunities

Partnership dealsLicensing discussionsVendor selection
Best for
Pharma executives Market access teams BD professionals Investors & analysts

Key Data to Watch

Presentations ranked by investor impact score

PLENARY Jun 3

Topline Results from the Phase 3 PEAK Trial: Tixagevimab/Cilgavimab for Pre-Exposure Prophylaxis of COVID-19

AstraZeneca tixagevimab(Evusheld) COVID-19 pre-exposure prophylaxis
INVESTOR IMPACT: ★★☆☆☆ 2/5
ORAL Jun 3

Phase 3 Results of Oral GLP-1 Receptor Agonist for Obesity

danuglipron Obesity
INVESTOR IMPACT: ★☆☆☆☆ 1/5
POSTER Jun 4

A Phase 3 Study of Oral Azacitidine (CC-486) Versus Placebo in Patients with Acute Myeloid Leukemia in First Remission

Bristol Myers Squibb azacitidine(Vidaza) Acute myeloid leukemia
INVESTOR IMPACT: ★☆☆☆☆ 1/5
ORAL Jun 5

Updated Results from Phase 1/2 Trial of TCR-T cell therapy in solid tumors

Immatics Solid tumors
INVESTOR IMPACT: ★☆☆☆☆ 1/5
ORAL Jun 5

Arcturus Therapeutics: Phase 3 Study of ARCT-810 (mRNA Therapeutic) for Ornithine Transcarbamylase Deficiency

Arcturus Therapeutics$ARCT Ornithine transcarbamylase deficiency
INVESTOR IMPACT: ★☆☆☆☆ 1/5
POSTER Jun 4

A Randomized Trial of Weekly Semaglutide in Overweight Adults with Type 2 Diabetes

semaglutide(Wegovy) Type 2 diabetes / overweight